Date Filed | Type | Description |
02/14/2022 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 0% stake in Adamas Pharmaceuticals, Inc. |
02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/26/2022 |
SC 13G/A
| Opaleye Management Inc. reports a 0% stake in Adamas Pharmaceuticals, Inc. |
12/10/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
12/06/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
12/02/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
11/24/2021 |
4
| BIGHAM MICHAEL (Director) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Unknown transaction of 10,000 shares
@ $0 Disposed/sold 10,000 options to buy
@ $4.8, valued at
$48k
Disposed/sold 10,000 options to buy
@ $2.7, valued at
$27k
Disposed/sold 10,000 options to buy
@ $5.21, valued at
$52.1k
|
|
11/24/2021 |
4
| MAHONEY DAVID L (Director) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Unknown transaction of 5,000 shares
@ $0 Unknown transaction of 112,781 shares
@ $0 Disposed/sold 10,000 options to buy
@ $4.8, valued at
$48k
Disposed/sold 40,000 options to buy
@ $6.08, valued at
$243.2k
Disposed/sold 10,000 options to buy
@ $2.7, valued at
$27k
Disposed/sold 10,000 options to buy
@ $5.21, valued at
$52.1k
|
|
11/24/2021 |
4
| McFarlane Neil F. (CEO) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Granted 75,000 shares
@ $0 Unknown transaction of 600,000 shares
@ $0 Disposed/sold 250,000 options to buy
@ $6.25, valued at
$1.6M
Disposed/sold 200,000 options to buy
@ $1.99, valued at
$398k
|
|
11/24/2021 |
4
| Prentiss Christopher B (CFO) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Granted 18,750 shares
@ $0 Unknown transaction of 163,767 shares
@ $0 Disposed/sold 37,500 options to buy
@ $6.81, valued at
$255.4k
Disposed/sold 50,000 options to buy
@ $4.7, valued at
$235k
|
|
11/24/2021 |
4
| Ericson William W. (10% Owner) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Unknown transaction of 10,000 shares
@ $0 Unknown transaction of 4,031,804 shares
@ $0 Unknown transaction of 6,043 shares
@ $0 Unknown transaction of 3,146 shares
@ $0 Unknown transaction of 25,661 shares
@ $0 Unknown transaction of 287,992 shares
@ $0 Unknown transaction of 265,150 shares
@ $0 Disposed/sold 10,000 options to buy
@ $4.8, valued at
$48k
Disposed/sold 10,000 options to buy
@ $2.7, valued at
$27k
Disposed/sold 10,000 options to buy
@ $5.21, valued at
$52.1k
|
|
11/24/2021 |
4
| Shreedhar Vijay (Chief Commercial Officer) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Granted 18,750 shares
@ $0 Unknown transaction of 186,786 shares
@ $0 Disposed/sold 137,500 options to buy
@ $4.67, valued at
$642.1k
Disposed/sold 47,500 options to buy
@ $2.32, valued at
$110.2k
|
|
11/24/2021 |
4
| Papapetropoulos Spyridon (Director) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Unknown transaction of 20,975 shares
@ $0 Disposed/sold 20,000 options to buy
@ $4.35, valued at
$87k
Disposed/sold 10,000 options to buy
@ $5.21, valued at
$52.1k
|
|
11/24/2021 |
4
| RICHO ANNA (Director) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Unknown transaction of 25,000 shares
@ $0 Disposed/sold 20,000 options to buy
@ $5.12, valued at
$102.4k
Disposed/sold 10,000 options to buy
@ $5.21, valued at
$52.1k
|
|
11/24/2021 |
4
| DEMSKI MARTHA J (Director) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Unknown transaction of 16,000 shares
@ $0 Unknown transaction of 5,000 shares
@ $0 Disposed/sold 10,000 options to buy
@ $4.8, valued at
$48k
Disposed/sold 10,000 options to buy
@ $2.7, valued at
$27k
Disposed/sold 10,000 options to buy
@ $5.21, valued at
$52.1k
|
|
11/24/2021 |
4
| MacPhee John A (Director) has filed a Form 4 on Adamas Pharmaceuticals Inc
Txns:
| Unknown transaction of 202,000 shares
@ $0 Disposed/sold 24,000 options to buy
@ $3.305, valued at
$79.3k
Disposed/sold 10,000 options to buy
@ $4.8, valued at
$48k
Disposed/sold 10,000 options to buy
@ $2.7, valued at
$27k
Disposed/sold 10,000 options to buy
@ $5.21, valued at
$52.1k
|
|
11/24/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
11/24/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
11/24/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
11/24/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
11/24/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
11/24/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
11/24/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
11/24/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
11/24/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
11/24/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
11/24/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
11/24/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
11/24/2021 |
8-K
| Resignation/termination of a director |
11/24/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
11/23/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
11/23/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
11/18/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
11/10/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
|